Prognostic effect of factors involved in revised Tokuhashi score system for patients with spinal metastases: a systematic review and Meta-analysis

Yang, Xiong‐gang; Lun, Dengxing; Hu, Yongcheng; Liu, Yong-Heng; Wang, Rui; Feng, Jiangtao; Hua, Kun‐chi; Yang, Li; Zhang, Hao; Xu, Ming‐you

doi:10.1186/s12885-018-5139-2

Cited by 12 publications

(3 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also found that for patients with spinal metastases, the difference in disease awareness had no signi cant impact on the survival time of patients. Compared with primary spinal tumors, spinal metastases had a worse survival and were closely related to the patient's disease conditions [34]. Therefore, the degree of disease awareness may have less in uence on the survival time of such patients, in addition to the symptoms caused by the primary tumor.…”

Section: Discussionmentioning

confidence: 99%

Study on the relationship between disease awareness and survival time in patients with spinal malignant tumors

Li,

Luo,

Tang

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose As a malignant tumor with high mortality, spinal malignant tumors often cause great trauma to patients and accompany low quality of life. Whether or not to inform patients of their condition has always been controversial in the medical community. This retrospective cohort study investigated the association between disease awareness and survival time in patients with spinal malignant tumors.Methods 129 patients with spinal malignant tumors were enrolled between January 2016 and December 2022, including 40 primary spinal tumors and 89 spinal metastases. The potential factors influencing spinal malignant tumor survival were registered, including disease awareness, age, gender, education level, pathological type, treatment, smoking history, drinking history, and survival time. All participants were followed up every 6 months until August 2023.Results In August 2023, 76 (58.9%) patients died, and 53 (41.0%) patients still survived. The 3-year survival rate of patients with primary spinal tumors was 70.4%, and that of patients with spinal metastases was 22.1%, with a median survival time (MST) of 12 months (95% confidence interval [CI], 9.69–14.31). Among the 129 participants, 16(12.4%) did not know their condition at all, 34(26.3%) only knew their diagnosis, 79(61.2%) knew not only their diagnosis but also the treatment and prognosis of the disease, and younger and more educated Patients with primary spinal tumors were more likely to have a complete understanding of the disease. Cox regression analysis showed that awareness of the disease (hazard ratio, 0.214;95% CI, 0.091–0.504; P < 0.001) and education level (hazard ratio,0.322;95% CI, 0.104–0.995; P < 0.05) were independent influencing factors for survival in patients with primary spinal tumors. However, the same results were not found in patients with spinal metastases.Conclusion A complete understanding of cancer knowledge may contribute to the better survival of patients with primary spinal tumors. Therefore, Medical staff could provide Patient Decision Aid for patients with primary spinal tumors to improve their disease cognition, achieve shared decision-making, and enhance the therapeutic effect, survival rate, and quality of life. At the same time, physicians should respect patients' cultural preferences and individual differences for patients with spinal metastases. In addition, medical staff should provide psychological support and education for patients and their families while encouraging patients to adopt positive coping strategies.

show abstract

Section: Discussionmentioning

confidence: 99%

Study on the relationship between disease awareness and survival time in patients with spinal malignant tumors

Li,

Luo,

Tang

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Most studies focus on bone metastases originating from a monotumour. It has been reported that patients with bone metastases in breast, prostate and thyroid cancer have superior prognoses than those with lung and gastrointestinal cancer 16–18. Accordingly, survival is related to the characteristics of primary tumours.…”

Section: Introductionmentioning

confidence: 99%

Prevalence and prognosis of bone metastases in common solid cancers at initial diagnosis: a population-based study

Zhang,

Cai,

Hong

2023

BMJ Open

View full text Add to dashboard Cite

ObjectiveBone is one of the most common target sites for advanced tumours. The objective was to survey the prevalence and prognosis of bone metastases in 12 common solid malignant tumours.DesignA retrospective cohort study.MethodsA total of 1 425 332 patients with a primary cancer between 2010 and 2015 were identified using the Surveillance, Epidemiology, and End Results database. We computed the prevalence and prognosis of bone metastases in each cancer and compared their survival in different stages. The Kaplan-Meier method and Cox logistic regression were used to analyse survival and quantify the effect of bone metastases.ResultsThis study included 89 782 patients with bone metastases at diagnosis. Lung cancer had the highest prevalence (18.05%), followed by liver cancer (6.63%), nasopharyngeal carcinoma (6.33%) and renal cancer (5.45%). Breast cancer (32.1%), prostate cancer (25.9%), thyroid cancer (46.9%) and nasopharyngeal carcinoma (24.8%) with only bone metastases had a 5-year survival rate of over 20%. Compared with patients at the stage previous to metastasis, bone metastases significantly increased the risk of mortality and decreased survival, especially for those with prostate cancer (adjusted HR: 18.24). Other concomitant extraosseous metastases worsened patient survival. Bone was the most common site of metastasis for prostate cancer, while for colorectal cancer, multiorgan metastases were predominant.ConclusionsThis study provides the prevalence and prognosis of bone metastases at the initial diagnosis of common solid cancers. In addition, it demonstrates the impact of bone metastases on survival. These results can be used for early screening of metastases, clinical trial design and assessment of prognosis.

show abstract

“…In most literature, data on bone metastases are based on a single tumor. Previous studies have reported that the prognoses of patients with breast, prostate and thyroid cancer with bone metastases are signi cantly superior to those of patients with lung and gastrointestinal cancer [16][17][18]. The survival of patients with bone metastases is related to the characteristics of their primary tumors.…”

Section: Introductionmentioning

confidence: 99%

Incidence and Prognosis of Bone Metastases in Common Solid Cancers at Initial Diagnosis: A Population-Based Study

Zhang

Hong

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Bone is one of the most common sites of advanced tumors. However, there is currently a lack of population-based surveys for the incidence and prognosis of bone metastases in common solid cancers.Methods Patients with 12 types of primary cancer and bone metastases at initial diagnosis between 2010 and 2015 were identified using the Surveillance, Epidemiology, and End Results (SEER) database. The Kaplan-Meier method and Cox logistic regression were conducted to analyze survival and the effect of bone metastases on different cancers.Results We included 89,782 patients with bone metastases at cancer diagnosis. Lung cancer had the highest incidence (17.61%) of bone metastases at diagnosis in any stage, followed by liver cancer (6.29%), nasopharyngeal carcinoma (6.22%) and renal cancer (5.19%). Among patients with breast and prostate cancer, only 3.4% and 4.39%, respectively, were identified as having bone metastases at diagnosis. Breast cancer (32.1%), prostate cancer (25.2%), thyroid cancer (46.8%) and nasopharyngeal carcinoma (24.8%) patients with only bone metastasis have an over 20% five-year survival rate. Compared with patients at a stage previous to metastasis, bone metastasis significantly increased the risk of mortality and reduced survival time, especially for patients with prostate cancer (HR: 19.64, 95% CI 18.36 to 21.02). Concomitant other organ metastases make patient survival worse. Regarding the metastases of prostate cancer, bone metastases are the main type, while for colorectal cancer, bone metastases and concomitant visceral metastases mainly occur.Conclusions The findings of this study provide estimates of the incidence and prognosis of patients with bone metastases during the initial diagnosis of common solid cancers. In addition, we also clarified the degree to which bone metastasis affects patient survival. Patient prognosis depends on the primary type of cancer. These results can be used as a reference for the screening of metastases, and the optimization of personalized treatment options to improve the quality of life and survival of patients.

show abstract

Prognostic effect of factors involved in revised Tokuhashi score system for patients with spinal metastases: a systematic review and Meta-analysis

Cited by 12 publications

References 80 publications

Study on the relationship between disease awareness and survival time in patients with spinal malignant tumors

Study on the relationship between disease awareness and survival time in patients with spinal malignant tumors

Prevalence and prognosis of bone metastases in common solid cancers at initial diagnosis: a population-based study

Incidence and Prognosis of Bone Metastases in Common Solid Cancers at Initial Diagnosis: A Population-Based Study

Contact Info

Product

Resources

About